Latest Regulatory News

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

AVJennings Limited has announced a special fully franked dividend of AUD 0.167 per share, contingent on court approval of a proposed scheme of arrangement with PM Nominees C Pty Ltd.

Horizon Gold Limited has announced a $7 million non-renounceable entitlement offer alongside a $5 million placement to fund its Gum Creek Gold Project and repay debt. The offer opens on 29 July and closes on 12 August 2025.

Cazaly Resources confirms robust gold mineralisation at Duke of York and discovers a promising new target, Duchess, at its Goongarrie Gold Project. Early drilling results and reprocessed geophysics set the stage for expanded exploration.

Blaze Minerals has completed its acquisition of an 80% interest in the Loulombo Base Metals Project in the Republic of the Congo and is advancing preparations for its maiden drilling campaign.

Elsight Limited reports unprecedented revenue growth in Q2 and H1 2025, driven by major defence contracts and expanding market demand. The company is on track to achieve profitability in the second half of the year.

Beacon Minerals has announced a $12 million on-market share buy-back program aiming to enhance shareholder value and capital efficiency, with purchases starting August 1, 2025.

Cleo Diagnostics reports steady progress in its ovarian cancer diagnostic test development, with clinical trial recruitment on track and strategic access to major biobanks enhancing its regulatory pathway.

Tivan and Sumitomo Corporation have formalised their joint venture for the Speewah Fluorite Project, securing a strategic investment from Japan’s JOGMEC. This partnership marks a significant step towards advancing the project’s feasibility and strengthening Australia-Japan critical minerals ties.

Elixir Energy has advanced its strategic plan in Queensland’s Taroom Trough, appointing a new COO, initiating a major cost reduction, and preparing to drill key exploration and appraisal wells that could unlock significant gas resources.

PainChek has completed its final FDA submission for the PainChek Adult App, targeting the US long-term care market with a potential $100 million annual opportunity. A regulatory decision is expected within 75 days, setting the stage for rapid commercialisation.

Lumos Diagnostics reported a 12% revenue increase for FY25 and inked a landmark US$317 million exclusive distribution deal for its FebriDx test, while advancing its FDA CLIA waiver application.